To treat or not to treat: CFTR modulators after lung transplantation

Don Hayes, Leanna K. Darland, Michelle A. Hjelm, Heidi M. Mansour, Kathryn A. Wikenheiser-Brokamp

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Evidence for the extrapulmonary benefits of (CFTR) modulators is rapidly expanding. The use of CFTR modulators in CF patients who have undergone lung transplantation is not clear without guidance published in the medical literature to assist clinicians in the care of these patients. We discuss the potential benefits of CFTR modulators and provide insight into their use based on our experience in a small cohort of CF LTx recipients. We present pros and cons of CFTR modulator therapy for LTx recipients with CF. CFTR modulators should be considered in CF patients after lung transplantation for the time being until further research defines how to best use these therapies in transplant recipients.

Original languageEnglish (US)
Article numbere14007
JournalPediatric transplantation
Issue number4
StatePublished - Jun 2021


  • CF
  • CFTR
  • LTx
  • modulator

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation


Dive into the research topics of 'To treat or not to treat: CFTR modulators after lung transplantation'. Together they form a unique fingerprint.

Cite this